dapi antibody Search Results


94
Thermo Fisher albumin polyclonal antibody coralite cl59416475 dapi thermofisher scientific
Albumin Polyclonal Antibody Coralite Cl59416475 Dapi Thermofisher Scientific, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc11324947__42003_2024_6661_MOESM2_ESM-0-40-46?v=Thermo+Fisher
Average 94 stars, based on 1 article reviews
albumin polyclonal antibody coralite cl59416475 dapi thermofisher scientific - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

98
Vector Laboratories id source h1200

Id Source H1200, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc05912906-14-7-4?v=Vector+Laboratories
Average 98 stars, based on 1 article reviews
id source h1200 - by Bioz Stars, 2026-07
98/100 stars
  Buy from Supplier

96
Vector Laboratories dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/bio_rxiv__2022__05__31__491513-88-3-6?v=Vector+Laboratories
Average 96 stars, based on 1 article reviews
dapi - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

90
Bioworld Antibodies dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi, supplied by Bioworld Antibodies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pm35172156-270-132-133?v=Bioworld+Antibodies
Average 90 stars, based on 1 article reviews
dapi - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Lonza fluorescently conjugated secondary antibody and dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Fluorescently Conjugated Secondary Antibody And Dapi, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/10__1016_slash_j__isci__2025__112105-545-25-26?v=Lonza
Average 90 stars, based on 1 article reviews
fluorescently conjugated secondary antibody and dapi - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Becton Dickinson dapi antibody
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc10281969__41467_2023_39423_MOESM1_ESM-3-43-39?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
dapi antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science dapi-goat anti-rabbit antibody
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi Goat Anti Rabbit Antibody, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc07339410-79-10-14?v=Beijing+Solarbio+Science
Average 90 stars, based on 1 article reviews
dapi-goat anti-rabbit antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Ribobio co secondary antibodies labeled fluorescence dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Secondary Antibodies Labeled Fluorescence Dapi, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc05407594-134-6-10?v=Ribobio+co
Average 90 stars, based on 1 article reviews
secondary antibodies labeled fluorescence dapi - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
CTR Scientific anti-dapi antibodies
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Anti Dapi Antibodies, supplied by CTR Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc09865178-113-26-27?v=CTR+Scientific
Average 90 stars, based on 1 article reviews
anti-dapi antibodies - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
CellSearch inc dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc04436118-44-17-18?v=CellSearch+inc
Average 90 stars, based on 1 article reviews
dapi - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science dapi and anti-gsdmd polyclonal antibody
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi And Anti Gsdmd Polyclonal Antibody, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pmc11446317__SC___015___D4SC03643C___s001-14-1-9?v=Beijing+Solarbio+Science
Average 90 stars, based on 1 article reviews
dapi and anti-gsdmd polyclonal antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
MBL Life science primary antibody against dapi dye
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Primary Antibody Against Dapi Dye, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dapi+antibody/pm37474360-132-14-18?v=MBL+Life+science
Average 90 stars, based on 1 article reviews
primary antibody against dapi dye - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Journal: eLife

Article Title: Adult-born neurons facilitate olfactory bulb pattern separation during task engagement

doi: 10.7554/eLife.33006

Figure Lengend Snippet:

Article Snippet: antibody , DAPI , Vector Labs , ID_source:H1200 , .

Techniques: Transfection, Plasmid Preparation, Software

Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) % GFAP+ cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% GFAP/DAPI+ cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).

Journal: bioRxiv

Article Title: Computational Identification of Ligand-Receptor Pairs that Drive Human Astrocyte Development

doi: 10.1101/2022.05.31.491513

Figure Lengend Snippet: Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) % GFAP+ cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% GFAP/DAPI+ cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).

Article Snippet: Antibodies used were DAPI (in VECTASHEILD, Vector Laboratories, Cat. H-1500), GFAP (DAKO, Cat. Z0334, dilution 1:1500), and Ki67 (BD, Cat. b550609, dilution 1:50).

Techniques: Activity Assay, MANN-WHITNEY, Expressing, Staining, RNA Sequencing Assay

Impact of candidate ligand exposures on fetal astrocytes. A . GW 17-20 cortices were immunopanned for CD49f+ immature astrocytes, which were cultured for 10 days in the presence or absence of the ligand cocktail. B . Astrocyte and neuronal gene signatures assessed by RNA-seq of CD490f+ cells. Fold change represents expression in ligand conditions vs control media (p < .001, Mann Whitney U). C . GFAP+ cell process traces from ligand-exposed and control CD49f+ fetal cells. Scale bar = 50 µm. D . GFAP+ cell process quantification. Primary branches extend from the nucleus. Secondary branches extend from primary branches. Boundary size is the area (x 10 3 µm 2 ) of the image field that one cell occupies. (*p<.01, **p<.001, *** p<.0001, Mann Whitney U). E . Timeline of EdU exposure. Fetal astrocytes were cultured for 8 days after purification with ligand exposure from days 1-7. EdU added at day 1 until duration of experiment. F . No significant change in percent of EdU+ nuclei between control and ligand-exposed cells. G . Representative images of DAPI and EdU+ cells after 8 days in culture.

Journal: bioRxiv

Article Title: Computational Identification of Ligand-Receptor Pairs that Drive Human Astrocyte Development

doi: 10.1101/2022.05.31.491513

Figure Lengend Snippet: Impact of candidate ligand exposures on fetal astrocytes. A . GW 17-20 cortices were immunopanned for CD49f+ immature astrocytes, which were cultured for 10 days in the presence or absence of the ligand cocktail. B . Astrocyte and neuronal gene signatures assessed by RNA-seq of CD490f+ cells. Fold change represents expression in ligand conditions vs control media (p < .001, Mann Whitney U). C . GFAP+ cell process traces from ligand-exposed and control CD49f+ fetal cells. Scale bar = 50 µm. D . GFAP+ cell process quantification. Primary branches extend from the nucleus. Secondary branches extend from primary branches. Boundary size is the area (x 10 3 µm 2 ) of the image field that one cell occupies. (*p<.01, **p<.001, *** p<.0001, Mann Whitney U). E . Timeline of EdU exposure. Fetal astrocytes were cultured for 8 days after purification with ligand exposure from days 1-7. EdU added at day 1 until duration of experiment. F . No significant change in percent of EdU+ nuclei between control and ligand-exposed cells. G . Representative images of DAPI and EdU+ cells after 8 days in culture.

Article Snippet: Antibodies used were DAPI (in VECTASHEILD, Vector Laboratories, Cat. H-1500), GFAP (DAKO, Cat. Z0334, dilution 1:1500), and Ki67 (BD, Cat. b550609, dilution 1:50).

Techniques: Cell Culture, RNA Sequencing Assay, Expressing, MANN-WHITNEY, Purification